We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
Read MoreHide Full Article
The second-quarter 2022 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.
While a few big pharma companies have reported, a major chunk of drug and biotech companies are slated to release results in the coming two weeks. The earnings picture looks reasonably well so far. Bellwether Johnson & Johnson beat estimates for both earnings and sales in the second quarter but the outlook was lowered. Biogen (BIIB - Free Report) beat on sales and earnings in the second quarter and the company upped its financial guidance. Novartis reported mixed results as earnings beat estimates but sales missed the mark.
The Earnings Trends report indicates that as of Jul 20, 8.9% of the companies in the Medical sector — representing 29% of the sector’s market capitalization — reported quarterly earnings. Earnings and revenues increased 10.4% and 11.2% year over year, respectively. Overall, second-quarter earnings and sales of the Medical sector are expected to rise 1.5% and 8.1%, respectively, from the year-ago quarter’s reported figures.
Let’s analyze the performance of the above-mentioned biotech/pharma companies.
Bristol Myers Squibb
Bristol Myers Squibb, which has an impressive earnings track record so far, is scheduled to report quarterly results before the market opens. The company beat earnings estimates in all of the last four quarters, the average surprise being 2.36%. In the last reported quarter, it beat earnings by 2.08%.
Eliquis and immuno-oncology drug Opdivo are likely to have driven growth in the second quarter. New drugs are likely to have fueled growth as well.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. This does not seem to be the case with Bristol Myers for the to-be-reported quarter. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Bristol Myers has an Earnings ESP of -2.10% and currently carries a Zacks Rank #3.
Bristol Myers Squibb Company Price and EPS Surprise
GSK will report second-quarter results before market open. Its earnings surpassed estimates in each of the trailing four quarters, delivering a beat of 24.09% on average.
Higher sales from newer respiratory and HIV drugs are likely to have been offset by a decline in sales of older HIV drugs and Established Pharmaceuticals segment sales.
GSK has an Earnings ESP of -4.32% and a Zacks Rank #5 (Strong Sell).
Alkermes’ earnings surprise history has been excellent so far, having surpassed expectations in each of the trailing four quarters, with an average beat of 350.48%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Vivitrol (for alcohol and opioid dependence), Aristada (for schizophrenia) and Vumerity and newly approved drug Lybalvi are likely to have maintained momentum for the company.
Teva will report results before market open. Teva’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average being a negative 0.42%,
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise
Teva has an Earnings ESP of +0.71% and a Zacks Rank #3.
Continued rise of Austedo prescriptions and market share growth for Ajovy might have boosted its performance. Cost-saving initiatives undertaken by the company are likely to have aided the bottom line.
Image: Bigstock
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
The second-quarter 2022 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.
While a few big pharma companies have reported, a major chunk of drug and biotech companies are slated to release results in the coming two weeks. The earnings picture looks reasonably well so far. Bellwether Johnson & Johnson beat estimates for both earnings and sales in the second quarter but the outlook was lowered. Biogen (BIIB - Free Report) beat on sales and earnings in the second quarter and the company upped its financial guidance. Novartis reported mixed results as earnings beat estimates but sales missed the mark.
The Earnings Trends report indicates that as of Jul 20, 8.9% of the companies in the Medical sector — representing 29% of the sector’s market capitalization — reported quarterly earnings. Earnings and revenues increased 10.4% and 11.2% year over year, respectively. Overall, second-quarter earnings and sales of the Medical sector are expected to rise 1.5% and 8.1%, respectively, from the year-ago quarter’s reported figures.
Bristol Myers Squibb (BMY - Free Report) , GSK plc (GSK - Free Report) , Teva Pharmaceutical Industries Limited (TEVA - Free Report) and Alkermes (ALKS - Free Report) are scheduled to release second-quarter earnings on Jul 27.
Let’s analyze the performance of the above-mentioned biotech/pharma companies.
Bristol Myers Squibb
Bristol Myers Squibb, which has an impressive earnings track record so far, is scheduled to report quarterly results before the market opens. The company beat earnings estimates in all of the last four quarters, the average surprise being 2.36%. In the last reported quarter, it beat earnings by 2.08%.
Eliquis and immuno-oncology drug Opdivo are likely to have driven growth in the second quarter. New drugs are likely to have fueled growth as well.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. This does not seem to be the case with Bristol Myers for the to-be-reported quarter. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Bristol Myers has an Earnings ESP of -2.10% and currently carries a Zacks Rank #3.
Bristol Myers Squibb Company Price and EPS Surprise
Bristol Myers Squibb Company price-eps-surprise | Bristol Myers Squibb Company Quote
GSK
GSK will report second-quarter results before market open. Its earnings surpassed estimates in each of the trailing four quarters, delivering a beat of 24.09% on average.
Higher sales from newer respiratory and HIV drugs are likely to have been offset by a decline in sales of older HIV drugs and Established Pharmaceuticals segment sales.
GSK has an Earnings ESP of -4.32% and a Zacks Rank #5 (Strong Sell).
GSK plc Price and EPS Surprise
GSK plc price-eps-surprise | GSK plc Quote
Alkermes
Alkermes’ earnings surprise history has been excellent so far, having surpassed expectations in each of the trailing four quarters, with an average beat of 350.48%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Vivitrol (for alcohol and opioid dependence), Aristada (for schizophrenia) and Vumerity and newly approved drug Lybalvi are likely to have maintained momentum for the company.
Alkermes has an Earnings ESP of +300.00% and a Zacks Rank #1, indicating an earnings surprise. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes plc Price and EPS Surprise
Alkermes plc price-eps-surprise | Alkermes plc Quote
Teva
Teva will report results before market open. Teva’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average being a negative 0.42%,
Teva Pharmaceutical Industries Ltd. Price and EPS Surprise
Teva Pharmaceutical Industries Ltd. price-eps-surprise | Teva Pharmaceutical Industries Ltd. Quote
Teva has an Earnings ESP of +0.71% and a Zacks Rank #3.
Continued rise of Austedo prescriptions and market share growth for Ajovy might have boosted its performance. Cost-saving initiatives undertaken by the company are likely to have aided the bottom line.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.